Broad Syntheses including this primary study

loading
8 articles (8 Referencias) Revertir Estudificar

Estudio primario

No clasificado

Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment.

Revista Schizophrenia research
Año 2010
Enlaces Pubmed DOI

Este artículo está incluido en 8 Revisiones sistemáticas Revisiones sistemáticas (8 referencias)

Cargando información sobre las referencias
Recent trials support the hypothesis of the role of inflammation in the pathogenesis of schizophrenia. The overall therapeutic benefit of anti-inflammatory medication, in particular cyclo-oxygenase-2 (COX-2) inhibitors in schizophrenia, is still controversial. There are suggestions that therapy with COX-2 inhibitors may influence the early stages of the disease. Taking these findings into account, we conducted a double-blind, placebo-controlled, randomized trial of celecoxib augmentation to amisulpride treatment in patients with a first manifestation of schizophrenia. Forty-nine patients diagnosed with schizophrenia were randomly assigned. They were treated either with amisulpride (200–1000mg) plus celecoxib (400mg) or amisulpride (200–1000mg) plus placebo. Inclusion criterion was the diagnosis of schizophrenia during the past two years according to DSM-IV. The trial lasted six weeks. At weekly intervals an assessment of the psychopathology was performed using the Positive and Negative Symptom Scale (PANSS) and the Global Clinical Impression Scale (CGI). A significantly better outcome was observed in the patient group treated with amisulpride plus celecoxib compared to the group with amisulpride plus placebo (PANSS negative: <i>p</i>=0.03; PANSS global; <i>p</i>=0.05 and PANSS total: <i>p</i>=0.02). In addition, ratings by the CGI scale during therapy with amisulpride and celecoxib showed a significantly better result (<i>p</i>≤0.001). A significantly superior therapeutic effect could be observed in the celecoxib group compared to placebo in the treatment of early stage schizophrenia. This is the first time an improvement in patients' negative symptoms has been demonstrated with celecoxib. In future, further trials are needed to investigate the effect of COX-2 inhibitors on prodromal and negative symptoms of schizophrenia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)

Estudio primario

No clasificado

Adjunctive celecoxib treatment with risperidone in first-episode schizophrenia: a double blind, randomized and placebo controlled trial

Revista Chinese Journal of Psychiatry
Año 2008

Este artículo está incluido en 1 Revisión sistemática Revisiones sistemáticas (1 referencia)

Cargando información sobre las referencias

Estudio primario

No clasificado

Adjunctive celecoxib treatment with clozapine in chronic refractory schizophrenia:a double blind,randomized and placebo controlled trial

Revista Sichuan Mental Health
Año 2008

Este artículo está incluido en 1 Revisión sistemática Revisiones sistemáticas (1 referencia)

Cargando información sobre las referencias

Estudio primario

No clasificado

Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial.

Revista Schizophrenia research
Año 2007
Enlaces Pubmed DOI

Este artículo está incluido en 7 Revisiones sistemáticas Revisiones sistemáticas (7 referencias)

Cargando información sobre las referencias
Some evidence suggests that the pathophysiology of schizophrenia is associated with the abnormal immune system, and cytokines may be important in schizophrenia. Cyclooxygenase-2 (COX-2) inhibitors such as celecoxib reduce the production of proinflammatory cytokines including Th1-like cytokines. Indeed, COX-2 inhibitors rebalance type-1 and type-2 immune response. The purpose of the present investigation was to assess the efficacy of celecoxib as an adjuvant agent in the treatment of chronic schizophrenia in an eight-week, double-blind and placebo-controlled trial. Eligible participants in this study were 60 patients with chronic schizophrenia. All patients were inpatients and were in the active phase of the illness, and met DSM-IV criteria for schizophrenia. Patients were allocated in a random fashion, 30 to risperidone 6 mg/day plus celecoxib 400 mg/day (200 mg bid) (morning and evening) and 30 to risperidone 6 mg/day plus placebo. Although both protocols significantly decreased the score of the positive, negative and general psychopathological symptoms over the trial period, the combination of risperidone and celecoxib showed a significant superiority over risperidone alone in the treatment of positive symptoms, general psychopathology symptoms as well as PANSS total scores. The means Extrapyramidal Symptoms Rating Scale for the placebo group were higher than in the celecoxib group over the trial. However, the differences were not significant. The results of this study suggest that celecoxib may be an effective adjuvant agent in the management of patients with chronic schizophrenia and anti-inflammatory therapies should be further investigated. (PsycInfo Database Record (c) 2021 APA, all rights reserved)

Estudio primario

No clasificado

Celecoxib Augmentation of Continuously III Patients with Schizophrenia.

Revista Biological psychiatry
Año 2005
Enlaces Pubmed DOI

Este artículo está incluido en 8 Revisiones sistemáticas Revisiones sistemáticas (8 referencias)

Cargando información sobre las referencias
BACKGROUND: Previous reports have demonstrated a beneficial effect of celecoxib adjunctive therapy for patients with an acute exacerbation of schizophrenia. We investigated the effects of celecoxib augmentation of atypical antipsychotic medications for continuously symptomatic outpatient subjects with schizophrenia to further extend these findings. We hypothesized that celecoxib augmentation therapy would improve psychopathology ratings compared with placebo. METHODS: Thirty-eight symptomatic outpatient subjects meeting DSM-IV criteria for schizophrenia and on a stable dose of an atypical antipsychotic medication for at least three months were randomized to receive 8 weeks of double blind placebo or celecoxib (400 mg/day) augmentation. Measures of psychopathology, functional disability, and extrapyramidal side effects were performed throughout the study. RESULTS: The treatment cohorts did not differ on any of the clinical outcome measures. CONCLUSIONS: Celecoxib augmentation of continuously ill outpatient subjects with schizophrenia did not improve clinical symptoms or measures of disability. (PsycInfo Database Record (c) 2021 APA, all rights reserved)

Hilo de publicación

Muller N, Müller N

Este hilo de publicación incluye 3 referencias

Estudio primario

No clasificado

Celecoxib add-on therapy does not have beneficial antipsychotic effects over risperidone alone in schizophrenia.

Autores Rappard, F , Mueller, N
Revista Neuropsychopharmacology
Año 2004

Este artículo está incluido en 6 Revisiones sistemáticas Revisiones sistemáticas (6 referencias)

Cargando información sobre las referencias

Estudio primario

No clasificado

Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia.

Revista The American journal of psychiatry
Año 2002
Enlaces Pubmed DOI

Este artículo está incluido en 7 Revisiones sistemáticas Revisiones sistemáticas (7 referencias)

Cargando información sobre las referencias
Conducted a trial of the new selective cyclooxygenase-2 inhibitor celecoxib, an immunomodulatory drug, in 50 schizophrenic patients (aged 18-65 yrs) with an acute exacerbation of schizophrenia. Ss were randomly assigned to either risperidone plus celecoxib or risperidone plus placebo. After washout, 25 patients received 2-6 mg/day of risperidone plus placebo and 25 received risperidone plus 400 mg/day of celecoxib for 5 wks. The treatment effect was calculated by analysis of covariance. There were no significant differences between groups in age, sex, duration or severity of disease or psychopathology, or risperidone dose or plasma level. Over 5 wks, both groups of patients showed significant improvement in scores on the Positive and Negative Syndrome Scale and on all subscales. However, the celecoxib group showed significantly greater improvement in the total score. Additional treatment with celecoxib has significant positive effects on the therapeutic action of risperidone with regard to total schizophrenia psychopathology. Moreover, the fact that treatment with an immunomodulatory drug showed beneficial effects on schizophrenia symptoms indicates that immune dysfunction in schizophrenia is not just an epiphenomenon but is related to the pathomechanism of the disorder. (PsycInfo Database Record (c) 2021 APA, all rights reserved)